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ABSTRACT 
Biodegradable nanoparticles are being considered more often as drug carriers to address 
pharmacokinetic/pharmacodynamic issues, yet nano-product safety has not been 
systematically proven. In this study, haematological, biochemical and histological parameters 
were examined on 28 day daily dosing of rats with nano- or micro-particle encapsulated 
cyclosporine (CsA) to confirm if any changes observed were drug or carrier dependent. CsA 
encapsulated poly(lactide-co-glycolide) [PLGA] nano- (nCsA) and micro-particles (mCsA) 
were prepared by emulsion techniques.  CsA (15, 30, 45 mg/kg) were administered by oral 
gavage to Sprague Dawley (SD) rats over 28 days. Haematological and biochemical metrics 
were followed with tissue histology performed on sacrifice. Whether presented as nCsA or 
mCsA, 45 mg/kg dose caused significant loss of body weight and lowered food consumption 
compared to untreated control. Across the doses, both nCsA and mCsA produce significant 
decreases in lymphocyte numbers compared to controls, commensurate with the proprietary 
product, Neoral®15. Dosing with nCsA showed higher serum drug levels than mCsA 
presumably owing to the smaller particle size facilitating absorption. The treatment had no 
noticeable effects on inflammatory/oxidative stress markers or antioxidant enzyme levels, 
except an increase in ceruloplasmin (CP) levels for high dose nCsA/mCsA group. Further, 
only subtle, sub-lethal changes were observed in histology of nCsA/mCsA treated rat organs. 
Blank (drug-free) particles did not induce changes in the parameters studied. Therefore, it is 
extremely important that the encapsulated drug in the nano-products is considered when 
safety of the overall product is assessed rather than relying on just the particle size. This 
study has addressed some concerns surrounding particulate drug delivery, demonstrating safe 
delivery of CsA whilst achieving augmented serum concentrations.  
Key Words: biodegradable, cyclosporine, microparticles, nanoparticles, nanotoxicology, 
oral, polyester, toxicity. 
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Introduction 
Cyclosporine (CsA) is a potent immunosuppressive drug widely used for prevention of graft 
rejection following transplantation (Barbier et al., 2013; Flechner et al., 2013). In addition, 
CsA alone or in combination with other immunosuppressant drugs is found to have benefit in 
diverse clinical conditions such as rheumatoid arthritis, psoriasis, traumatic brain injury or 
glucocorticoid-dependent idiopathic nephrotic syndrome (Gremese et al., 2004; Sullivan et 
al., 2011; Colombo et al., 2013; Iyengar et al., 2013; Mrowietz 2013). The side effects, 
however, of CsA such as nephrotoxicity and hypertension often outweigh its benefit.  
 
Beyond immunosuppression, CsA also appears to have activity in metabolic disorders. 
Recently, preclinical reports suggest that CsA can be beneficial in managing obesity in diet-
induced obese mice (Jiang et al., 2013); conversely clinical data in transplant patients suggest 
CsA can result in hyperlipidemia with marked increases in total and LDL cholesterol as well 
as triglycerides (reviewed in Wissing and Pipeleers 2013). CsA proved better than other 
calcineurin inhibitors, e.g. tacrolimus, in avoiding post-transplant diabetes mellitus due to 
poor allograft outcomes in renal transplants (Choi and Kwon 2013), that could be further 
improved with better pharmaceutical delivery of CsA (Italia et al., 2006 & 2007; Ankola et 
al., 2010 & 2011; Park et al., 2013).  
 
Whichever indication, it is widely reported that conventional CsA microemulsion 
formulations exhibit variable bioavailability with consequently differing biological activity 
(Ready 2004; Qazi et al., 2006). Moreover, titrating CsA dose whilst avoiding drug 
interactions within the requisite polypharmacy regimens selected to treat transplant patients 
with infection can be complicated (Frassetto et al., 2014). Research efforts are therefore 
aimed at reformulating CsA to maximize benefits by addressing not only the variable 
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bioavailability but toxicity problems (Azzi et al., 2010; Italia et al., 2007; Ankola et al., 2010 
&2011; Kadam et al., 2012).   
 
There has been much debate in the literature surrounding the question of particle size cut-off 
of non-conventional (nanoparticle) formulations for drug uptake following oral dosing; recent 
studies suggest smaller (0.5 µm) vehicles lead to greater up-take compared to larger (5 µm)  
(Reineke et al., 2013). Indeed the vast majority of reports on non-conventional CsA 
preparations has focussed on drug bioavailability enhancement in vivo (Italia et al., 2007; 
Ankola et al., 2010 & 2011; Park et al., 2013) without consideration of possible influence on 
organ or system physiology and function (Lucas et al., 2005; Moss and Siccardi 2014). 
Though the pharmacokinetic/pharmacodynamic properties of CsA and its maintenance within 
its narrow therapeutic window is important, understanding the pathophysiological effect of 
nano-carriers themselves has become equally or more important considering the growing 
concerns of nanotoxicology (Devadasu et al., 2013; Lamprou et al., 2013).  Very recently, we 
demonstrated for the first time the utility of “atomic force microscopy (AFM) for visualizing 
label-free CsA encapsulated polylactide-co-glycolide (PLGA) nanoparticle distribution 
within the tissues following intravenous or peroral administration (Lamprou et al., 2013). 
 
Since we have obtained the first proof of drug encapsulated nanoparticles being absorbed 
intact across the intestine (Lamprou et al., 2013), we designed the present study to assess any 
haematological or biochemical changes consequent to encapsulation of CsA in PLGA nano- 
(<300nm) and micro-particles (>1 µm) with a view to establishing the safety profile of long-
term dosing with such particulates as well as serum drug concentration as a correlative 
indicator of bioavailability.  
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Materials and methods 
Materials 
PLGA 50:50 (Resomer® RG 503 H; intrinsic viscosity 0.32-0.44 dL/g) was purchased from 
Boehringer Ingelheim (Ingelheim, Germany, now Evonik Industries). CsA was purchased 
from Flurochem Ltd., (Hadfield, Derbyshire, UK). Polyvinyl alcohol (PVA) (Mol. Wt. 
30,000-70,000) was purchased from Sigma-Aldrich (Irvine, UK). Organic solvents and 
mobile phases for HPLC such as ethyl acetate and acetone (analytical reagent grade), glacial 
acetic acid, methanol (MeOH; HPLC grade) and acetonitrile (ACN; HPLC grade) were 
purchased from Fisher Scientific (Loughborough, UK). Ultrapure Milli-Q® water (in house 
supply) was used for all experiments. 
 
Preparation of CsA encapsulated PLGA nano- and micro-particles  
PLGA (500 mg) and CsA (75 mg) were dissolved in ethyl acetate (25 mL) with stirring at 
1000 rpm over a 2 h period. Drug containing polymer solution was then added drop-wise to 
50 mL 1% (w/v) PVA solution. The resulting primary emulsion (o/w) was stirred over 1 h at 
1000 rpm. For reduction of droplet size, primary emulsions were homogenised (Polytron PT 
4000, Kinematica, Switzerland) for 30 min at 15,600 or 8,600 rpm for nanoparticle or 
microparticle preparation, respectively.  The emulsion was transferred to 250 mL of water 
and stirred overnight to facilitate diffusion of organic solvent and evaporation. The CsA 
encapsulated particle suspension was pelleted by centrifugation at 14,000g for 30 min. The 
entrapment efficiency was measured by previously developed HPLC method (Italia et al., 
2007; Ankola et al., 2010 & 2011). Blank nano- and micro-particles were prepared as 
described without addition of CsA. 
 
Freeze drying 
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The particle pellets were re-suspended in 30 mL water to which 5% (w/v) sucrose was added 
and vortexed until dissolution. The particle suspension (4 mL) was placed in 5mL glass vials 
and frozen at −80°C overnight. Freeze drying process was carried out using a bench top 
freeze drier system (MicroModulyo®230, Thermo Electron Corporation, Ohio, USA) 
operating at −50°C under high vacuum (0.003 mBar) for 48 h to ensure a dried product. The 
freeze dried nCsA and mCsA were re-suspended in 4 mL of distilled water for further 
characterization and in vivo study. 
 
In vivo study design 
The repeated dose oral toxicity study was carried out at the Biological Procedures Unit 
(BPU), University of Strathclyde. All procedures on animals were performed according to 
project licence (PLL 60/3920) under the Animals (Scientific Procedures) Act 1986 (UK). 
 
Animals, housing and feeding conditions  
Eight week old Sprague Dawley (SD) male rats were housed in polypropylene cages under 
standard conditions of temperature (24±1oC) and relative humidity (55±10%), in 12 h light 
and 12 h dark cycles throughout the experiment. Animals had free access to food and water. 
 
Dosing of formulations to animals 
Forty rats were randomly divided into ten groups as shown in Table 1. The rats received 
peroral dosing of approximately 1mL of each formulation by oral gavage daily for 28 days. 
The four control groups were dosed similarly with equal volume of vehicle only, blank nano- 
or micro-particles, or Neoral for 28 days. 
 
General observation, body weight and food intake 
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Throughout the study period, observations were made daily for general health of the animals 
and signs of acute toxicity e.g. locomotor activity, prostration, rapid shallow breathing, 
pallor, profound dullness. Prior to dosing, the rats’ weights were recorded at a fixed time 
using a calibrated balance. To monitor food consumption, a weighed amount of standard 
pellet diet was placed in the food tray of the cage. Any leftover pellets were weighed and 
replaced with fresh pellets each day. Feeding time was fixed throughout the study. 
 
Blood sampling and measurement of CsA concentration in serum   
At the end of the 28 day study period, the animals were fasted overnight and euthanized the 
following day by CO2 asphyxiation.  Blood samples were collected by cardiac puncture in 
heparinized syringes and transferred into EDTA tubes or plasma/serum separation tubes for 
blood analysis and CsA concentrations respectively. The concentrations of CsA in serum 
after 28 days study period were determined using commercially available Cyclosporine EIA 
Kits (Immunotech, Czech Republic) (Ankola et al., 2010 & 2011). 
 
Estimation of blood urea nitrogen (BUN) and plasma creatinine (PC) levels 
Plasma was separated from whole blood by centrifugation at 3000 rpm for 15 min at 5oC. The 
BUN and PC were determined calorimetrically using commercially available kits (Cayman 
Chemicals Ltd.). 
 
Oxidative stress, inflammation and antioxidant enzyme levels 
The degree of oxidative stress/inflammation caused by the treatment was assessed by 
measuring fibrinogen (FBG), C-Reactive Protein (CRP), ceruloplasmin (CP) levels and 
monitoring their effect on the endogenous antioxidant enzyme levels e.g. superoxide 
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dismutase (SOD) and catalases (CAT). Protein quantification was carried out using 
commercially available ELISA kits (Cayman Chemicals Ltd.).  
 
Haematological parameters 
A fully automated haematology analyser (Hemavet 950FS, Drew Scientific Inc, USA) was 
used to measure the following parameters in blood: haemoglobin (Hb), red blood corpuscles 
count (RBC), white blood corpuscles count (WBC), and differential leukocyte count (DLC). 
Blood films were analysed after standard haematoxylin and eosin staining. 
 
Flow cytometry for CD90 expression 
Peripheral blood mononuclear cells were stained with phycoerythrin (PE) conjugated mouse 
anti-rat CD90 (Thy-1) (BD Pharmingen; Clone OX-7) for 15 minutes on ice and unbound 
antibody washed off in phosphate buffered saline (PBS) by centrifugation at 192g for 5 
minutes. The pellet was re-suspended and after red cell lysis with EasyLyse™ (Alere Ltd., 
Stockport, UK), total mononuclear cells were analysed by flow cytometry on a BD 
Bioscience FACS Canto II with Diva software with an initial gate on live cells based on the 
forward (FSC) and side scatter properties (SSC) of viable cells. Doublets were then excluded 
based on the ratio of the area versus width of the pulse generated by single cells.  Within the 
viable, single cell population, cells expressing CD90 on their cell surface were identified. 
Finally to determine the percentage of haemopoietic stem/progenitor cells (HSPC) 
specifically, the cells with high CD90 expression were back gated into FSC/SSC to identify a 
subpopulation of cells which are likely true HSPC based on their distinct physical properties 
of size and granularity.  
  
Urine analysis 
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Urine samples were collected at the end of the study period and analysed for appearance, pH, 
protein and blood traces. 
 
Histopathological evaluation 
Heart, kidney, liver, testis, spleen, lung, brain and small intestine were isolated immediately 
on sacrifice. The tissues were washed with ice-cold saline and weighed before fixing in 10% 
neutral buffered formalin solution. The tissues were then embedded in paraffin blocks and 
used for histopathological examination. Five micrometre thick sections were cut, de-
paraffinised, hydrated and stained with haematoxylin and eosin. The histological sections 
were examined under microscope (Leitz, Wetzlar, Germany) for any morphological changes. 
In case of kidney, the diameters of the glomerular capillary tuft (CD) and Bowman's capsule 
(BD) were measured with the help of an internal micrometer and the CD/BD ratio was 
calculated as an index of glomerular collapse (Origlia et al., 2006). 
 
Statistical Analysis 
The data are presented as mean ± standard deviation. ANOVA models were used to compare 
the treatment groups.  Additionally, the least squares means were obtained for all groups 
under considerations and multiple comparison tests of the least squares mean differences 
were performed following the overall test for the treatment effect.  The Tukey method was 
used to adjust the p values for the multiple comparisons.  A p value of less than 0.05 was 
considered to be statistically significant. 
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Results 
Evaluation of nCsA and mCsA 
The freeze dried nCsA, mCsA or blank (drug void) particles were easily reconstituted in 
water by simple shaking. The particles had an average size of 280.2±25 nm and 1.21±0.22 
µm with polydispersity index of 0.231 and 0.301 for nCsA and mCsA, respectively (SI 
Figure 1a,b). The entrapment efficiency of freshly prepared particulates was found to be 
about 55±6% for both nCsA and mCsA which did not change significantly after freeze 
drying. To further characterise the microparticle size distribution, mCsA were subjected to 
differential centrifugation at 2000, 5000 and 6500 g (SI Figure 2a-c). The mCsA preparations 
were found to contain a large population of nanoparticles.  
 
General observation, body weight of animals and food intake 
Thorough physical examinations were carried out every day during the study period for signs 
of morbidity. No unusual variations in locomotor activity or signs of intoxication or ataxia 
were observed during the 28 day study period. Hair loss was noted in high dose nCsA and 
mCsA (45mg/kg) treated rats. Daily eye examinations did not show any dose related 
abnormalities in any treated group. During the treatment period, significant loss of body 
weight (Figure 1a,b) with reduced food consumption (Figure 2a,b) were observed in high 
dose nCsA and mCsA treated animals during the first two week period; these animals never 
reached normal weight. The weight loss was not statistically significant between the nCsA 
and mCsA (45mg/kg) treated groups. The control animals gained weight as did rats treated 
with 15 or 30 mg/kg CsA. 
 
CsA concentration in serum 
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CsA concentrations in serum were measured 24 h after the last administered dose (Figure 3). 
A dose dependent increase of CsA concentration was observed across all formulations, 
though nCsA and mCsA did not differ in their levels with the exception of 15 mg/kg group.  
 
BUN and PC analysis 
Significant elevation of BUN was observed across all treatment groups compared to control; 
a dose response was evident (Figure 4a). However, PC levels were not significantly different 
across all treatment groups and were similar to controls (Figure 4b). 
 
Oxidative stress, inflammation and antioxidant enzyme levels 
Data was gathered on markers of oxidative stress/inflammation (CRP, FBG and CP) and 
endogenous antioxidant enzyme levels (CAT and SOD). All the markers, except CP, did not 
change across all the treatment groups compared to control (Table 2). CP was increased 
significantly on treatment with high dose nCsA or mCsA (45mg/kg) while the other groups 
including Neoral remained unchanged compared to control. The increase in CP was found 
to be independent of inflammatory markers or endogenous antioxidant levels.  
 
Haematological parameters 
Although there was a general, non-statistically significant trend towards lower total WBC in 
all CsA treatment groups with the exception of low dose nCsA or mCsA, with respect to 
untreated or blank particle controls (SI Table 1), statistically significant differences in 
(increased) neutrophil and (decreased) lymphocyte proportions (as percent contribution) were 
noted when a differential count was performed (Table 3). Erythrocyte numbers and 
parameters e.g. haemoglobin, were found to be unchanged across all groups when compared 
to control (SI Table 2). A significant increase in platelet count was only observed in Neoral® 
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treated rats (Table 4) with respect to control; while all other treatments were significantly 
lower than Neoral®. No gross abnormalities or differences in morphology were observed on 
blood film examination. 
 
Haematopoietic stem/progenitor (CD90+) cells in peripheral blood 
The effect of the particle formulations on more primitive haematopoietic cells were next 
examined to see whether the treatments had had subtle effects on cells found earlier in the 
developmental hierarchy i.e. on haematopoietic stem/progenitor (CD90+) cells (Figure 5). 
The Neoral® did not significantly restrict homeostatic CD90+ cell appearance in the 
peripheral blood (0.07±0.01 versus 0.09±0.05%, Neoral® versus untreated control), neither 
did nCsA/mCsA nor blank (drug void) particles (SI Figure 3).   
 
Urine analysis 
Urine samples from control and treated rats were collected over time. The urine pH of all the 
groups was alkaline and traces of protein were found, but not blood. 
 
Histopathological examination 
Insignificant variations were observed in relative organ weights (SI Table 3), when 
comparison was made between test and control groups. Histopathological assessment 
confirmed the integrity of tissue morphology and architecture of various organs after long-
term daily dosing over 28 days (Figure 6 and SI Figure 4&5), including target organs for CsA 
toxicity (e.g. kidney); there were no major areas of confluent tissue necrosis or inflammation. 
However, subtle sub-lethal cell changes could not be ruled out on examination of these tissue 
sections. 
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Discussion and conclusion 
The nano- and micro-particles were prepared in large scale in sufficient quantities for our 
sub-acute toxicity study. The particles were successfully freeze dried resulting in easily 
reconstituted cake with comparable attributes of fresh preparations (particle size and 
entrapment efficiencies). A dose dependent increase in serum CsA levels was noted across 
the doses and mCsA generally showed much higher levels (almost comparable to nCsA) than 
anticipated owing to the presence of a significant proportion of nanoparticles in mCsA 
preparations (Figure 3; SI Figure 2a-c). Although there is no agreement on the cut-off for 
particle size for optimal peroral absorption, it is a relative phenomenon whereby smaller is 
generally believed to be better (Mittal et al., 2007; Reineke et al., 2013).  
 
The animals on high dose nCsA or mCsA (45 mg/kg/day) showed a significant reduction in 
the body weight during the first two weeks of the treatment that was proportional to food 
intake (Figures 1-2). The weight loss correlated with high CsA serum concentration (Figure 
3).  Notably an equivalent dose of blank (drug void) particles did not cause loss of body 
weight (Figure 1a,b) and all the other groups showed weight gain or maintained their weight 
over the duration of the study. This data is in agreement with literature where it is reported 
that very high doses of CsA (50 mg/kg/day) result in short periods of anorexia and reduced 
food intake; however when food intake becomes normal, and as we observed in our study, the 
animals do not regain normal weight (Farthing et al., 1981). A recent report demonstrated 
that dosing with 10 mg/kg/day CsA for 3 weeks  attenuated weight gain of mice fed a high fat 
diet over the preceding 8 weeks while non-obese mouse weight remained constant (Jiang et 
al., 2013). The authors went on to claim that CsA could stimulate leptin signal transduction in 
the hypothalamus of obese mice which was responsible for the weight loss.  
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The serum concentration measurements made at the end of this current study demonstrated a 
dose response as the CsA levels in the blood increased proportionally with dose administered 
in agreement with our previous report (Ankola et al., 2011). Although statistically significant 
differences were seen between nCsA and mCsA, the numerical differences in absolute values 
between these two groups were not large especially between groups in the high dose cohort 
(Figure 3). It has been reported in the literature that particle sizes < 2 µm are absorbed 
through the lymphatic system in lower numbers than particles up to 500 nm in size 
(Mathiowitz et al., 1997, Desai et al., 1996; Reineke et al., 2013). The wide size distribution 
range in our mCsA preparation and comparable serum CsA concentration with either mCsA 
or nCsA, prompted us to do differential centrifugation to apportion the contribution made of 
nanoparticles to the mCsA preparation (SI Figure 2a-c). There were significant numbers of 
nanoparticles within the microparticle formulation that could have led to the comparable 
though statistically significant concentration profiles of CsA administered as nano- or micro-
particles (Figure 3). The serum CsA concentrations reflected the BUN but not PC levels; 
however, BUN levels across all doses were not too different from Neoral 15 mg dose, while 
significantly different from untreated (Figure 4). We believe this gives comfort to the 
possibility of dose escalation offered when administering nano- or micro-particulate CsA, 
which is in agreement with previous reports (Farthing et al., 1981; Ankola et al., 2011).  The 
terminal urine analysis showed no abnormalities, all the samples were alkaline pH with some 
traces of protein which was normal (Hall et al., 2008).  
 
Foreign bodies such as nano-delivery vehicles may cause mild or severe hematologic toxicity 
that can be life-threatening, clinically all the more pertinent in the organ transplant setting 
when patients are treated with CsA. In our in vivo study, leukocyte and erythrocyte counts for 
blank (drug void) particle treated groups were similar to controls suggesting mitigation of 
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inherent carrier mediated toxicity because of their size (Table 3 and SI Tables 1-2). A 
decreasing trend in absolute lymphocyte numbers was observed across the particle treated 
groups comparable to the lymphocytopenia seen with Neoral, which is a predicted CsA 
dependent phenomenon. Indeed, the reduction in the proportion of lymphocytes in the total 
white cell count did gain statistical significance with CsA treatment by differential counts. 
CsA is known to increase platelet activation/aggregation increasing the risk of 
thromboembolic complications and hypertension (Reis et al., 2000). Significantly higher 
platelet counts were observed in Neoral treated rats but not with nCsA or mCsA at any dose; 
the mean platelet volume (MPV) remained the same across all CsA treatments.  No abnormal 
variations were observed in erythrocyte counts or red cell parameters across all doses which, 
together with the platelet result, suggested the particulate carrier could deliver higher doses of 
CsA without increasing off-target toxicity. The antioxidant enzymes and pro-inflammatory 
cytokines measured did not alter from control with particulate CsA delivery again indicating 
the safety profile of the formulations. That said, a recent publication (Lv et al., 2013) has 
linked CP levels to acute Graft versus Host Disease in the allogeneic stem cell transplant 
setting, a condition associated with immune reactions and inflammatory cytokine storm. The 
increase in plasma CP seen in our study may be associated with the higher plasma levels of 
CsA achieved with highest dose particulate drug delivery as Neoral® or low dose and blank 
particles did not precipitate a significant increase in the protein; again reiterating the safety of 
particles. 
 
Therefore it was interesting to further evaluate the effect of CsA encapsulated particulates on 
the immune system given not only that the drug is used as an immunosuppressant but 
importantly, that nano-vehicles innately travel, by virtue of their size, to the organs of the 
mononuclear phagocyte system such as the spleen or bone marrow.  This is not often 
16 
 
considered. Whilst the steady state appearance of rat bone marrow haematopoietic 
stem/progenitor (CD90+) cells in the peripheral blood seemed to be negatively modulated by 
high dose mCsA, there was no clear relationship to particle size or payload concentration as 
neither blank (drug void) nano-/micro-particles nor low dose mCsA (15mg/kg) inhibited 
CD90+ cell mobilisation.  Indeed the latter had significantly higher number of CD90+ cells 
detectable in the blood with respect to high dose mCsA (45mg/kg) but notably this increase 
in number was not significantly different from untreated control. Whether mCsA affected 
CD90+ cell turnover and self-renewal could be determined in a colony forming cell assay. We 
hypothesise however, that our haematological findings reflect the natural range of distribution 
of CD90+ cells in the blood and is not linked to pathology or toxicity as the apparent 
inhibition seen with mCsA was statistically different from the Neoral® but not untreated 
control group which exhibited the widest variation around its mean. 
 
No significant changes observed in percent relative organ weight supported the presumption 
of normal functioning of target organs, phospholipid metabolism, and enzyme secretion. 
Indeed post mortem histological examination of kidneys from all the treatment groups 
revealed normal renal cortex, glomerular tubules and renal papilla comparable to control.  
Hepatocytes and portal tracts in liver sections seemed normal across all groups suggesting 
lack of inflammatory infiltration during the study period. All the cardiac tissue sections 
assessed showed normal myocardium with no pigment deposition. Normal alveolar 
architecture and cellular infiltrations was observed in lung sections from both control and 
treated groups. The testis sections of control and all treated groups showed active 
spermatogenesis and maturation and normal shape and size of seminiferous tubules. Splenic 
architecture with normal red and white pulp was observed in control groups similar to the 
treatment groups (Figure 6; SI Figures 4-5).  
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In summary, our data indicates that daily dosing with CsA encapsulated PLGA nano- or 
micro-particles over 28 days did not cause any deleterious general health effects attributable 
to the carrier. Although high dose nCsA/mCsA (45mg/kg) did cause significant loss of body 
weight, this was in keeping with reported toxicity of Neoral. No significant haematological 
or biochemical changes were recorded on long-term dosing with either nCsA/mCsA.  Despite 
the presence of nanoparticles in the microparticle formulation, the nCsA product consistently 
resulted in higher serum drug concentration thus the particulates allow an increase in dose 
range without accrual of toxicities. 
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Figure legends 
Figure 1  
Percentage body weight of rats on repeated dosing with (a) nCsA or (b) mCsA at different 
doses.  
Figure 2  
Food consumption of rats on long-term dosing with (a) nCsA and (b) mCsA at different 
doses. 
Figure 3  
Serum concentration of CsA at the end of the study.  
 
Figure 4  
Nephrotoxic indicators (i) BUN and (ii) PC levels of rats at the end of the study.  
 
Figure 5  
CD90+ cell detection in peripheral blood at the end of the study. 
A-D. After red cell lysis, total mononuclear cells were analysed by flow cytometry for live 
cells based on forward (FSC) and side scatter properties (SSC) of viable cells [Panel A]. 
Doublets were then excluded (based on the ratio of the area versus width of the pulse 
generated by single cells) [Panel B].  Within the single cell, viable subpopulation, CD90 cell 
surface expression was determined [Panel C]. To determine the percentage of haemopoietic 
stem/progenitor cells (HSPC) specifically, the cells with high CD90 expression were back 
gated into FSC/SSC [Panel D]; HSPC are boxed. 
E-F Representative overlaid histograms for CD90 expression and corresponding back-gated 
CD90high events into FSC/SSC dot plots are shown for animals treated with Neoral® 
(15mg/kg) (red); high dose mCsA (45mg/kg) (green); and untreated control (blue).   
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Figure 6  
Renal and hepatic histology at the end of the study. 
 
Table Legends 
Table 1  
Randomisation of rats for oral toxicity study. 
Table 2  
Plasma markers indicative of oxidative stress and inflammation markers, and antioxidant 
enzyme levels at the end of the study. 
Table 3  
Differential white cell counts at the end of the study. 
Table 4  
Platelet count (PTL) and mean platelet volume (MPV) at the end of the study. 
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Supplemental Information (SI) 
SI Figure 1. Particle size distribution of (a) nCsA and (b) mCsA. 
SI Figure 2. Nanoparticles in the supernatants of mCsA preparation after differential 
centrifugation at (a) 2000, (b) 5000 and (c) 6500 g. 
SI Figure 3. Percentage of CD90+ cells in rat peripheral blood at the end of the study. Results 
are mean ± standard deviation. 
SI Figure 4. Haematoxylin and eosin (H&E) stained histology sections of heart and lung at 
the end of the study. 
SI Figure 5. Haematoxylin and eosin (H&E) stained histology sections of spleen and testis at 
the end of the study.  
SI Table 1 Absolute white cell counts at the end of the study. 
SI Table 2 Erythrocyte numbers at the end of the study. 
SI Table 3 Percent relative organ weight at the end of the study. 
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Characterization 
Particle size and entrapment efficiency 
The size of nanoparticles and microparticles were determined using dynamic light scattering (DLS) 
technique (Zetasizer and Mastasizer Malvern, UK) by taking the average of 5 measurements. The 
polydispersity index (PDI) and uniformity which is a dimensionless number indicating the width of the size 
distribution, having a value between 0 and 1 (0 being for monodispersed particles) was also obtained. 
Entrapment efficiency was determined by centrifuging the nCsA and mCsA at 14,000 g for 30 min and 
separating the supernatant. The pellet was dissolved in acetonitrile and analysed by thermo HPLC system 
(Thermo, USA) consisting of Photodiode Array (PDA) detector. All separations were achieved on the 
Thermo ODS 100 RP-18 (250 X 4.6 mm) end-capped 5 µm column (Thermo, USA) maintained at 70 °C.  
Acetonitrile:methanol:0.05 M phosphoric acid (45:40:15) was used as mobile phase at flow rate of 1 ml/ 
min. The detection wavelength was 210 nm. 
 
SI Figure 1. Particle size distribution of (a) nCsA and (b) mCsA. 
 
 SI Figure 2. Nanoparticles in the supernatants of mCsA preparation after differential centrifugation at (a) 
2000, (b) 5000 and (c) 6500 g. 
  
NDC 0.09 ± 0.05
nCsA (45) 0.07 ± 0.05
mCsA (45) 0.04 ± 0.02
nCsA (15) 0.07 ± 0.04
mCsA (15) 0.09 ± 0.02
Blank nano 0.07 ± 0.02
Blank micro 0.07 ± 0.004
Neoral® (15) 0.07 ± 0.01
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C
*** *
*
 
 
 
SI Figure 3.  Percentage of CD90+ cells in rat peripheral blood at the end of the study. Results are mean ± 
standard deviation. 
 
 
 
 SI Figure 4. Haematoxylin and eosin (H&E) stained histology sections of heart and lung at the end of the 
study. 
 
 
 
 
 
 
 
 
 
 
 
 SI Figure 5. Haematoxylin and eosin (H&E) stained histology sections of spleen and testis at the end of the 
study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
SI Table 1. Absolute white cell counts at the end of the study. 
Groups WBC (K/µL) NE (K/µL) LY (K/µL) MO (K/µL) EO (K/µL) BA (K/µL) 
Control 8.05 ± 2.64 2.18 ± 0.79 5.44 ± 1.75 0.36 ± 0.27 0.05 ± 0.05 0.01 ± 0.01 
Neoral® 15 6.54 ± 1.31 3.13 ± 0.91 2.85 ± 0.93 0.54 ± 0.08 0.02 ± 0.01 0.01 ± 0.01 
nCsA 45 6.07 ± 2.59 2.86 ± 1.15 2.63 ± 1.25 0.56 ± 0.22 0.01 ± 0.01 0.00 ± 0.01 
mCsA 45 4.10 ± 0.71 2.47 ± 0.27 1.36 ± 0.35* 0.34 ± 0.09 0.02 ± 0.02 0.00 ± 0.00 
nCsA 30 7.75 ± 2.82 2.94 ± 0.85 4.15 ± 2.57 0.63 ± 0.23 0.02 ± 0.02 0.00 ± 0.01 
mCsA 30 5.72 ± 1.99 2.68 ± 1.00 2.50 ± 0.69 0.54 ± 0.32 0.01 ± 0.01 0.00 ± 0.01 
nCsA 15 8.07 ± 1.29 3.65 ± 0.95 3.64 ± 0.29 0.79 ± 0.32 0.08 ± 0.08 0.03 ± 0.04 
mCsA 15 9.73 ± 3.35 4.87 ± 1.62* 4.13 ± 1.60 0.69 ± 0.43 0.06 ± 0.06 0.01 ± 0.01 
nBlank 8.78 ± 2.95 2.70 ± 1.03 5.57 ± 1.94 0.44 ± 0.12 0.06 ± 0.06 0.01 ± 0.01 
mBlank 9.76 ± 2.64 2.63 ± 0.85 6.53 ± 1.71 0.54 ± 0.11 0.04 ± 0.01 0.01 ± 0.00 
Significant difference compared to control *Pd0.05 
SI Table 2. Erythrocyte numbers at the end of the study. 
Parameters RBC (M/µL) Hb (g/dL) HCT (%) MCV (fL) MCH (pg) MCHC (g/dL) RDW (%) 
Control 7.48 ± 1.49 14.85 ± 3.78 42.98 ± 9.68 57.28 ± 1.53 19.73 ± 1.35 34.45 ± 1.93 13.78 ± 0.46 
Neoral 15 7.72 ± 1.14 13.88 ± 1.88 41.78 ± 5.52 54.20 ± 0.92 18.00 ± 0.65 33.20 ± 1.29 14.68 ± 0.28 
nCsA 45 7.26 ± 1.85 14.27 ± 3.95 41.23 ± 10.6 56.70 ± 1.87 19.57 ± 0.97 34.50 ± 0.72 16.20 ± 1.06 
mCsA 45 6.25 ± 0.71 11.57 ± 1.33 34.40 ± 3.90 55.07 ± 0.06 18.50 ± 0.10 33.63 ± 0.31 15.33 ± 0.49 
nCsA 30 8.39 ± 0.46 15.16 ± 0.30 47.20 ± 2.02 56.20 ± 0.70 18.06 ± 0.72 32.13 ± 0.83 15.40 ± 0.26 
mCsA 30 8.51 ± 0.49 16.77 ± 1.30 48.23 ± 2.57 56.70 ± 0.30 19.77 ± 1.88 34.83 ± 3.14 15.87 ± 0.42 
nCsA 15 8.59 ± 0.62 17.70 ± 0.90 47.90 ± 2.97 55.80 ± 0.71 20.65 ± 0.91 37.00 ± 1.58 15.48 ± 0.75 
mCsA 15 8.57 ± 0.01 17.90 ± 0.26 48.86 ± 0.15 57.06 ± 0.25 20.90 ± 0.26 36.63 ± 0.68 15.26 ± 0.98 
nBlank 9.07 ± 0.22 18.23 ± 0.36 50.35 ± 0.93 55.48 ± 0.94 20.10 ± 0.16 36.20 ± 0.45 14.28 ± 0.26 
mBlank 9.15 ± 0.45 18.50 ± 0.46 49.93 ± 1.58 54.65 ± 1.86 20.25 ± 0.91 37.08 ± 0.71 14.48 ± 0.51 
SI Table 3. Percent relative organ weight at the end of the study. 
 
Heart Brain Lung Liver Small Intestine Spleen Kidney Testis 
Control 0.40 ± 0.03 0.45 ± 0.06 0.63 ± 0.12 2.86 ± 0.28 1.84 ±0.18 0.28 ± 0.01 0.77 ± 0.09 1.04 ± 0.04 
Neoral® 15 0.39 ± 0.03 0.51 ± 0.05 0.51 ± 0.09 3.23 ± 0.16 1.80 ± 0.21 0.27 ± 0.04 0.72 ± 0.08 0.97 ± 0.06 
nCsA 45 0.43 ± 0.11 0.58 ± 0.12 0.64 ± 0.05 3.17 ± 0.20 2.34 ± 0.15 0.23 ± 0.06 0.64 ± 0.05 1.02 ± 0.23 
mCsA 45 0.36 ± 0.08 0.60 ± 0.04 0.68 ±0.11 3.09 ± 0.27 1.99 ± 0.08 0.28 ± 0.04 0.68 ± 0.10 0.88 ± 0.15 
nCsA 30 0.43 ± 0.05 0.48 ± 0.08 0.56 ± 0.09 2.94 ± 0.10 2.01 ± 0.33 0.29 ± 0.01 0.67 ± 0.06 1.05 ± 0.04 
mCsA 30 0.42 ± 0.10 0.50 ± 0.09 0.50 ± 0.11 3.56 ±0.50 1.99 ± 0.12 0.35 ± 0.10 0.80 ± 0.08 1.00 ±0.15 
nCsA 15 0.45 ± 0.05 0.55 ± 0.08 0.47 ± 0.02 2.26 ± 1.19 1.64 ± 0.77 0.35 ± 0.09 0.70 ± 0.18 0.90 ± 0.28 
mCsA 15 0.47 ± 0.03 0.57 ± 0.09 0.56 ± 0.07 3.34 ± 0.29 1.82 ± 0.08 0.30 ± 0.01 0.91 ± 0.14 1.06 ± 0.13 
nBlank 0.39 ± 0.07 0.49 ±  0.13 0.53 ± 0.22 1.66 ± 1.45 0.91 ± 0.59 0.32 ± 0.13 0.57 ± 0.21 0.82 ± 0.49 
mBlank 0.34 ± 0.09 0.57 ± 0.10 0.56 ± 0.07 2.73 ± 0.26 1.44 ±0.11 0.26 ±0.04 0.76 ± 0.04 1.10 ±0.13 
 
 
Table 1. Randomisation of rats for oral toxicity study. 
Group Treatment mg/Kg/day 
Control ----- 
Neoral® 15 15 
nCsA 45 45 
mCsA 45 45 
nCsA 30 30 
mCsA 30 30 
nCsA 15 15 
mCsA 15 15 
nBlank* Eqv. to 45 of CsA 
mBlank** Eqv. to 45 of CsA 
*CsA-void nanoparticles; **CsA-void microparticles 
 
 
Table 2. Plasma markers indicative of oxidative stress and inflammation, and antioxidant enzyme levels at the end of the study. 
Group  CRP (µg/ml) FBG (µg/ml) CP (µg/ml) SOD (nmol/min/ml) CAT (U/ml) 
Control 1695.78 ± 15.71 950.23 ± 65.89 540.10 ± 104.75 1063.24 ± 153.24 114.56 ± 9.85 
Neoral 15 1712.41 ± 26.06 931.01 ± 93.19 792.64 ± 199.22 960.13 ± 51.26 121.63 ± 43.26 
nCsA 45 1717.53 ± 51.55 1034.69 ± 43.15 1242.07 ± 384.46* 1040.50 ± 219.94 152.34 ± 29.54 
mCsA 45 1706.65 ± 56.43 1004.97 ± 171.71 1295.33 ± 234.91** 1135.07 ± 269.14 154.51 ± 23.23 
nCsA 30 1716.25 ± 14.91 857.49 ±  74.12 977.56 ± 206.99 1024.33 ± 55.27 136.81 ± 17.87 
mCsA 30 1698.34 ± 8.65 874.03 ± 153.50 907.54 ± 353.27 1047.62 ± 55.32 119.04 ± 9.98 
nCsA 15 1697.06 ± 23.69 935.03 ± 127.19 766.90± 134.41 1063.83 ± 45.68 114.35 ± 12.38 
mCsA 15 1689.38 ± 4.83 967.66 ± 91.77 840.51 ± 164.74 1119.24 ± 146.85 117.85 ± 26.82 
nBlank 1661.87 ± 17.42 931.90 ± 60.00 815.98 ± 152.67 1024.49 ± 81.53 107.29 ± 16.56 
mBlank 1691.94 ± 16.73 941.51 ± 113.44 720.83 ± 184.81 1119.91 ± 209.26 117.57 ± 27.23 
Significant difference compared to control *Pd0.05, **Pd0.01 
 
Table 3. Differential white cell counts at the end of the study. 
 
Parameters NE LY MO EO BA 
Control 27.29 ± 5.19 67.80 ± 6.26 4.15 ± 1.76 0.60 ± 0.30 0.16 ± 0.13 
Neoral® 15 47.60 ± 8.69** 43.44 ± 8.98*** 8.69 ± 3.28 0.20 ± 0.05 0.06 ± 0.04 
nCsA 45 47.87 ± 4.53** 42.52 ± 5.06** 9.31 ± 0.68 0.22 ± 0.12 0.07 ± 0.11 
mCsA 45 59.15 ± 5.09*** 32.22 ± 4.88*** 8.09 ± 1.01 0.44 ± 0.32 0.10 ± 0.01 
nCsA 30 40.42 ± 16.30 50.91 ± 15.12 8.35 ± 2.57 0.27 ± 0.15 0.04 ± 0.05 
mCsA 30 46.62 ± 2.79* 44.37 ± 5.31** 8.86 ± 2.68 0.11 ± 0.03 0.03 ± 0.04 
nCsA 15 44.68 ± 4.84* 44.36 ± 6.78** 9.64 ± 2.87* 0.97 ± 1.05 0.36 ± 0.50 
mCsA 15 50.08 ± 1.80** 42.07 ± 4.51*** 6.92 ± 2.82 0.84 ± 1.03 0.09 ± 0.05 
nBlank 30.76 ± 3.34 63.21 ± 3.69 5.16 ± 1.06 0.77 ± 0.91 0.10 ± 0.09 
mBlank 26.70 ± 2.69 67.11 ± 2.49 5.68 ± 0.43 0.39 ± 0.19 0.13 ± 0.05 
Significant difference compared to control *Pd0.05, **Pd0.01 and ***Pd0.001 
 
Table 4. Platelet (PLT) count and mean platelet volume (MPV) at the end of the study. 
 
Parameters PLT (K/µL) MPV (fL) 
Control 799 ± 172 5.9 ± 0.35 
Neoral 15 2137 ± 106** 5.6 ± 0.48 
nCsA 45 745 ± 393*a 6.0 ± 0.60 
mCsA 45 1053 ± 443*a 5.1 ± 0.78 
nCsA 30 814 ± 123*a 5.9 ± 0.28 
mCsA 30 925 ± 100*a 5.9 ± 0.29 
nCsA 15 695 ± 137***a 5.8 ± 0.50 
mCsA 15 907 ± 182*a 5.8 ± 0.40 
nBlank 947 ± 870*a 5.8 ± 0.18 
mBlank 1004 ± 145*a 5.7 ± 0.33 
Significant difference Neoral vs control; a vs Neoral *Pd0.05, **Pd0.01 and ***Pd0.001 
 
 
  






